Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ipertensione

Bibliografia

Quali fonti bibliografiche considerare per l'Ipertensione?

Le informazioni contenute nella ricerca Pharmamedix dedicata all’ipertensione sono state analizzate dalla redazione scientifica con riferimento alle seguenti fonti.

  1. Appel L.J. et al., Hypertension, 2006, 47 (2), 296.
  2. Arch. Intern. Med., 1980, 140 (10), 1280.
  3. Asia Pacific Cohort Studies Collaboration, Circulation, 2005, 112 (22), 3384.
  4. Bang L.E. et al., Blood Press. Monit., 2000, 5 (5-6), 271.
  5. Bangalore S. et al., J. Am. Coll. Cardiol., 2009, 53, A217.
  6. Bangalore S. et al., Circulation, 2010, 122 (21), 2142.
  7. Bao D.Q. et al., Hypertension, 1998, 32 (4), 710.
  8. Beckett N.S. et al., NEJM, 2008, 358 (18), 1887.
  9. Bliziotis I.A. et al., J. Hypertens., 2012, 30 (7), 1289.
  10. Blood Pressure Lowering Treatment Trialists’ Collaboration, Lancet, 2003, 362 (9395), 1527.
  11. Bobrie G. et al., J. Hypertens., 2008, 26 (9), 1715.
  12. Boggia J. et al., Lancet, 2007, 370 (9594), 1219.
  13. Capasso F. et al., Fitoterapia - Impiego razionale delle dorghe vegetali, 1999, Springer.
  14. Coiro S. et al., Eur. J. Heart Fail., 2017, 19 (2), 271.
  15. Chen X., Wang Y., Circulation, 2008, 117 (25), 3171.
  16. Chow C.K. et al., JAMA, 2013, 310 (9), 959.
  17. Collins R. et al., Lancet, 1990, 335 (8693), 827.
  18. Conen D. et al., Circulation, 2009, 119 (16), 2146.
  19. Cornelissen V.A., Fagard R.H., Hypertension, 2005, 46 (4), 667.
  20. Cornelissen V.A., Fagard R.H., J. Hypertens., 2005a, 23 (2), 251.
  21. Cutler J.A. et al., Am. J. Clin. Nutr., 1997, 65 (Suppl. 2), S643.
  22. Daniels S.R. et al., Hypertension., 1996, 28 (1), 37.
  23. de la Sierra A. et al., J. Hypertens., 2012, 30 (4), 713.
  24. Dickinson H.O. et al., J. Hypertens, 2006, 24 (2), 215.
  25. Doll R. et al., BMJ, 1994, 309 (6959), 901.
  26. Domenech M. et al., Hypertension 2014, 64 (1), 69.
  27. Ercoli A., Clinica medica in fitogemmoterapia e omeopatia, 2002, Tecniche Nuove.
  28. Estruch R. et al., NEJM, 2018, 378 (25); e34.
  29. Eur. Heart J., 2007, 28 (12), 1462.
  30. Fagard R.H. et al., Eur. J. Cardiovasc. Prev. Rehabil., 2005, 12 (4), 326.
  31. Fagard R.H., Cornelissen V.A., J. Hypertens., 2007, 25 (11), 2193.
  32. Fagard R.H. et al., Hypertension, 2008, 51 (1), 55.
  33. Fagard R.H. et al., Blood Press. Monit., 2008a, 13 (6), 325.
  34. Fagard R.H. et al., Hypertension, 2009, 54 (5), 1084.
  35. Firenzuoli F., Fitoterapia - Guida all’uso clinico delle piante medicinali, 2009, Elsevier-Masson.
  36. Flynn J.T., Pediatr. Nephrol., 2000, 15 (3-4), 302.
  37. Flynn J.T. et al., Prog. Pediatr. Cardiol., 2001, 12 (2), 177.
  38. Flynn J.T., Alderman M.H., Pediatr. Nephrol., 2005, 20 (7), 961.
  39. Franklin S.S. et al., Circulation, 1997, 96 (1), 308.
  40. Franklin S.S. et al., Hypertension, 2012, 59 (3), 564.
  41. Gaborieau V. et al., J. Hypertens., 2008, 26 (10), 1919.
  42. Geleijnse J.M. et al., J. Hypertens., 2002, 20 (8), 1493.
  43. Griffith L.E. et al., Am. J. Hypertens., 1999, 12 (1 Pt 1), 84.
  44. Grundvold I. et al., Hupertension, 2012, 59 (2), 198.
  45. He F.J. et al., Hypertension, 2001, 38 (3), 321.
  46. He J., Whelton P.K., Clin. Exp. Hypertens., 1999, 21 (5-6), 785.
  47. He J. et al., J. Hypertens., 2004, 22 (1), 73.
  48. He F.J., Mac Gregor G.A., Hypertension, 2006, 48 (5), 861.
  49. Hodgkinson J. et al., BMJ, 2011, 342, d3621.
  50. Istituto Superiore di Sanità, Progetto Cuore, 2009, disponibile on line http://www.cuore.iss.it/fattori/pressione.asp.
  51. JAMA, 1977, 237 (3), 255.
  52. James P.A. et al, JAMA, 2014, 311 (5), 507 (Linee Guida JNC VIII, Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure).
  53. Jee S.H. et al., Am. J. Hypertens., 2002, 15, 691.
  54. Jennings G.L., J. Hypertens., 1997, 15 (8), 567.
  55. Joyce J.J. et al., Am. J. Cardiol., 2004, 93 (6), 797.
  56. Jung F.F., Ingelfinger J.R., Pediatr. Rev., 1993, 14 (5), 169.
  57. Kannel W.B. et al., Am. Heart J., 1987, 113 (6), 1489.
  58. Kannel, Am. J. Hyperten., 2000, 13 (Supll. 1), S3.
  59. Kavey R.E. et al., J. Pediatr., 2007, 150 (5), 491.
  60. Koren M.J. et al., Am. J. Hypertens, 2002, 15 (12), 1021.
  61. Lancet, 2002, 360 (9349), 1903.
  62. Law M.R. et al., Am. J. Hypertens., 1997, 10 (Suppl. 5), S42.
  63. Law M.R. et al., BMJ, 2009, 338, b1665.
  64. Lawes C.M.M. et al., J. Hypertens, 2006, 24 (3), 413.
  65. Lindholt J.S., Sogaard R., Lancet, 2017, 390 (10109), 2256.
  66. Lurbe E. et al., J Hypertens., 2009, 27 (9), 1719.
  67. Lv J et al., CMAJ, 2013, 185 (11), 949.
  68. MacMhaon S. et al., Lancet, 1990, 335 (8692), 765.
  69. Malhotra R. et al., JAMA Intern. Med., 2017, 177 (10), 1498.
  70. Mancia G. et al., Hypertension, 2006, 47 (5), 846.
  71. Mancia G. et al., Ipertensione e prevenzione cardiovascolare, 2010, vol 17, n 1.
  72. Mancia G. et al., J. Hypertens., 2013, 31 (7), 1281 disponibile on line http://www.eshonline.org/Guidelines/ArterialHypertension.aspx
  73. Mann S.J. et al., JAMA, 1991, 265 (17), 2226.
  74. Mann J.F. et al., Lancet, 2008, 372 (9638), 547.
  75. Manolis A. et al., J. Hypertension, 2013, 31 (11), 2109.
  76. Manson J.E. et al., NEJM, 1992, 326 (21), 1406.
  77. Margetts B.M. et al., BMJ, 1986, 293 (6560), 1468.
  78. Masci Walter, Omeopatia - Tradizione e attualità, 2003, Tecniche Nuove.
  79. Mente A. et al., Arch. Intern. Med., 2009, 169 (7), 659.
  80. Messerli F.H. et al., Ann. Intern. Med., 2006, 144 (12), 884.
  81. Minutolo R. et al., Arch. Intern. Med., 2011, 171 (12), 1090.
  82. Muller M. et al., 27th Annual Scientific Meeting and Exposition ASH, 2012, 19-22 maggio, New York, abstract LB-OR-01.
  83. Multiple Risk Factor Intervention Trial Research Group, Prev. Med., 1986, 15, 254.
  84. Nerenberg K.A. et al., CJC, 2018, 34 (5), 506 (Linee Guida CHEP, Canadian Hypertension Education Program) https://guidelines.hypertension.ca/ (accesso: novembre 2018).
  85. Neter J.E. et al., Hypertension, 2003, 42 (5), 878.
  86. NICE, Hypertension in adults: diagnosis and management 2016 (Linee Guida NICE 2016) www.nice.org.uk/guidance/cg127 (accesso: novembre 2018).
  87. O’Brien E. et al., Hypertension, 2007, 49 (2), 276.
  88. Okin P.M. et al., Circulation, 2003, 108 (6), 684.
  89. Omvik P., Blood Press., 1996, 5 (2), 71.
  90. ONTARGET Investigators, NEJM, 2008, 358 (15), 1547.
  91. Otten J. et al., The Dietary reference intakes, 2006, Washington DC: National Academies Press.
  92. Palatini P. et al., Arch Intern. Med., 2002, 162 (20), 2313.
  93. Palatini P. et al., J. Hypertens, 2006, 24 (4), 603.
  94. Parati G. et al., J. Hypertens., 2014, 32 (7), 1359.
  95. Parving H.H. et al., NEJM, 2008, 358 (23), 2433.
  96. Parving H.H. et al., NEJM, 2012, 367 (23), 2204.
  97. PATS Collaborating Group, Chin. Med. J. (Engl), 1995, 108 (9), 710.
  98. Pickering T. et al., JAMA, 1988, 259 (2), 225.
  99. Pierdomenico S.D, Cuccurullo F., Am. J. Hypertens., 2011, 24 (1), 52.
  100. PROGRESS Collaborative Group, Lancet, 2001, 358 (9287), 1033.
  101. Puddy I.B. et al., Addiction Biol., 1997, 2 (2), 159.
  102. Rimm E.B. et al., BMJ, 1999, 319 (7224), 1523.
  103. Robertson J.J. et al., J. Eval. Clin. Pract., 2003, 9 (1), 1.
  104. Robinson R.F. et al., Am. J. Hypertens., 2005, 18 (7), 917.
  105. Rosenberg L. et al., NEJM, 1985, 313 (24), 1511.
  106. Sacks et al., NEJM, 2001, 344 (1), 3.
  107. Schmieder R.E. et al., Lancet, 2007, 369 (9568), 1208.
  108. Seed A. et al., Eur. J. Heart Fail., 2007, 9 (11), 1120.
  109. Seltzer C.C., Am. Heart J., 1974, 87 (5), 558.
  110. Sleight P. et al., J. Hypertens, 2009, 27 (7), 1360.
  111. SNLG-ISS, Linee Guida sul Management dei pazienti con ipertensione arteriosa, 2008, disponibile online http://www.snlg-iss.it/banca_dati_comparativa#
  112. Sofi F. et al., Am. J. Clin. Nutr., 2010, 92 (5), 1189.
  113. Stamler J., Ann. Epidemiol., 1991, 1 (4), 347.
  114. Stergiou et al., Hypertension, 2010, 55 (6), 1301.
  115. Strocchi E., Lezioni di Patologia Generale, 2011, AMS Acta, Università di Bologna.
  116. The Trial of Hypertension Prevention Collaborative Group, Arch. Intern. Med., 1997, 157 (6), 657.
  117. Themopoulos C. et al., J. Hypertens., 2017, 35 (5), 922.
  118. Tumbull F. et al., Lancet 2003, 362 (9395), 1527.
  119. Tumbull F. et al., Arch. Intern. Med., 2005, 165 (12), 1410.
  120. VA/DoD Clinical Practice Guideline – Diagnosis and Management of Hypertension in Primary Care Setting, 2014 (Linee Guida VA/DoD 2014) www.healthquality.va.gov/guidelines/CD/htn/ (accesso: novembre 2018).
  121. Verdecchia P. et al., Hypertension, 2005, 46 (2), 386.
  122. Vidal-Petiot E. et al., Lancet, 2016, 388 (10056), 2142.
  123. Villamil A. et al., J. Hypertens., 2007, 25 (1), 217.
  124. Wannamethee S.G., Shaper A.G., Stroke, 1996, 27 (6), 1033.
  125. Ward A.M. et al., J. Hypertens., 2012, 30 (3), 449.
  126. WHO - World Health Organisation, 1993, Research guidelines for evaluating the safety and efficacy of herbal medicines.
  127. William B. et al., Eur. Heart J., 2018, 39 (33), 3021 (Linee Guida ESH/ESC 2018).
  128. World Health Organization/Inernational Society of Hypertension Writing Group, J. Hypertens., 2003, 21 (11), 1983.
  129. Wingen A.M. et al., Lancet, 1997, 349 (9059), 1117.
  130. Wuhl E. et al., J. Hypertens, 2002, 20 (10), 1995.
  131. Zanchetti A., J. Hypertens., 2009, 27 (8), 1509.
  132. Zangara A., Terapia medica ragionata delle malattie del cuore e dei vasi, 2000, Piccin.